• There are no suggestions because the search field is empty.

What is EUDAMED and what new requirements should medical device companies take into account?

Author Avatar
An-Katrien Pauwels, Life Sciences Consultant at QbD Group
Regulatory Affairs
The new medical device regulations and the associated implementation of EUDAMED are intended to give the general public access to relevant information on medical devices, ensuring greater transparency. However, EUDAMED also brings new requirements for market participants throughout the life cycle of medical devices. Read more about them here!
What is EUDAMED and what new requirements should medical device companies take into account? | QbD Group
8:39

 

The new medical device regulations and the associated implementation of EUDAMED should give the general public access to relevant information about medical devices and thus provide more transparency.

We can only encourage this, but EUDAMED also comes with new requirements for market participants present throughout the life cycle of medical devices. Learn more about these new requirements below! 

 

What is EUDAMED?

EUDAMED – the European Database on Medical Devices – was launched to exchange information between the European Commission (EC) and national competent authorities. The development and implementation of this IT system is a high priority for the Commission. It has been developed to implement the MDR or Medical Devices Regulation (EU) 2017/745 and Regulation (EU) 2017/746 on in vitro diagnostic medical devices.

EUDAMED aims to visualize the life cycle of medical devices made in the European Union (EU) and available on the European market. This secure, web-based portal will act as an interpretable registration, collaboration, reporting, and dissemination system accessible to the public.

The overall transparency of information would improve with EUDAMED. It provides national competent authorities, such as healthcare professionals, with quick and easy access to relevant regulatory information. Information coordination between the different EU Member States will also be improved to implement a unified approach to the Medical Device Directives.

 

EUDAMED’s 6 modules: an overview

The EUDAMED database is built around 6 interconnected modules and a public website. The EUDAMED modules include:

  1. actor registration,
  2. unique device identifier (UDI) and device registration,
  3. notified bodies and certificates,
  4. clinical and performance studies,
  5. vigilance,
  6. and market surveillance.

and will contain some of the following data:

  • registration of manufacturers,
  • their authorized representative and the devices in particular,
  • declaration of conformity,
  • monitoring and traceability system (declaration or ISO certificate),
  • labeling and instructions,
  • justification of the classification,
  • copy of ISO certificate or proof of QMS,
  • information from clinical studies,
  • Etc.
Below, we briefly explain each EUDAMED module. 
 

1. Actor Registration module

The EUDAMED Actor Registration Module was the first module to become available in December 2020 to the following actors:

  • regulatory bodies (such as EC, competent/designating authorities, notified bodies),
  • economic operators (such as manufacturers, procedure kit/system manufacturers, importers, and authorized representatives)

and sponsors of clinical/performance studies.

This module allows the registration of the various actors in the field of medical devices. Actors must enter data such as name, address, information about the person in charge of regulatory compliance, website, etc. to obtain an actor identifier/single registration number (Actor ID/SRN). Most of the information about actors will be available to the public.

Looking for an EU or non-EU manufacturer, system/procedure packaging producer, authorized representative or importer?

Click here to visit the EUDAMED Actor Registration Module 

 

2. Unique Device Identifier (UDI) modul

The second module, UDI and Device Identification and Device Registration, is for medical device registration and allows system/procedure package manufacturers and manufacturers to enter and update UDI core data elements of medical devices, and to register legacy devices.

This module became available in October 2021, except for the Clinical Assessment Consultation Procedure (CEDP) and the Review Mechanism. The CEDP procedure and the mechanism for scrutiny of the second module will be released when EUDAMED is fully functional together with the remaining modules. The full functionality of the database is expected to be launched in May 2022.

Do you want to search for UDI-DI and device data including SS(C)P?

Click here to visit the EUDAMED UDI Module 

 

 3. Notified Bodies & Certificates module

The third module is intended to enable communication between notified bodies and makes it possible to make the summaries of safety and clinical performance and their assessment reports of notified bodies available to the public.

It contains information about notified bodies, such as information about their appointed experts. Apart from that, there are several processes managed by EUDAMED notified bodies. The main one relates to the issuance of CE marking certificates, a process that also includes the refusal, restriction, suspension or revocation of a certificate.

Read more about the EUDAMED Notified Bodies & Certificates Module 

 

4. Clinical Investigation module

The Clinical Investigation module is the fourth module of EUDAMED. This module covers the management of data from clinical trials and performance studies for IVDs.

The main actor for this module is the sponsor, who, together with any of the competent authorities involved, can make important notifications and changes to the status of the study.

At the time this blog post was published, this module was not yet operational. Please check this link for the latest status. 

 

5. Vigilance module

Like the Clinical Research module, the Vigilance module has multiple actors working together in a process. Manufacturers may report trends in incidents that are not serious incidents or for which adverse events are expected that show a statistically significant increase in frequency or severity.

These Trend Reports must be uploaded and made available to the appropriate Competent Authorities and Notified Bodies. Vigilance is the most complex module to manage, as the consequences of an error or misunderstanding can be the greatest.

At the time this blog post was published, this module was not yet operationalPlease check this link for the latest status. 

6. Market Surveillance module

Part of EUDAMED is being established to facilitate coordination and cooperation between Member States. This module allows Member States to upload their summaries of market surveillance results, as well as reports of inspections carried out on economic operators.

This information will be kept almost entirely between the competent authorities and the European Commission. Notified bodies also have access to information about device certifications in which they are involved. The summary reports of the Member State’s market surveillance activities will also be publicly available.

At the time this blog post was published, this module was not yet operational. Please check this link for the latest status.

 

What EUDAMED data will be publicly available?

EUDAMED is partially open to the public. Among others, the following items will be publicly available from the launch of EUDAMED, or from the moment they are uploaded to the database:

  • identities of economic operators and sponsors,
  • restricted datasets of devices,
  • nomenclature codes for medical devices and their descriptions,
  • list of notified bodies designated,
  • issued and refused CE marking certificates,
  • summaries of safety and clinical performance,
  • applications and notifications for clinical investigations or performance studies, except for notifications of withdrawn applications,
  • reported adverse reactions and device defects,
  • summaries of clinical studies or performance studies before devices or within one year of submission to EUDAMED,
  • summary reports of the Member States’ market surveillance activities.

Other items may become publicly available at a later stage. Information that was not publicly accessible in EUDAMED at the time of entry will remain confidential. 

 

What should be your next steps?

 

The full implementation of EUDAMED has been postponed a few times already, at the time this blogpost was published, three modules were available.

The remaining three modules (Clinical Investigations and Performance Studies, Vigilance and Post-Market Surveillance , and Market Surveillance) are expected to be launched when EUDAMED if fully operational in May 2022.

Therefore, please keep a close eye on the EUDAMED website.

In case you still have questions on the correct application of EUDAMED on your specific device or your specific role within the lifecycle of medical devices, don’t hesitate to contact us. Our experts are happy to assist you!

 

Stay ahead in life sciences

Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.

Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.

Circles-banner-short

Discover more expert content

preview_image
Whitepaper

Regulatory Affairs for Pharma and Biotech

In this flyer, you will learn more about the regulatory services QbD Group provides for the pharmaceutical and biotechnology industries.
preview_image
Whitepaper

Clinical Evaluation for Medical Devices under MDR

This whitepaper will guide you through crucial regulatory documents pertaining to the clinical evaluation process of your medical device. Download now!
preview_image
Whitepaper

IVDR extension: what does this mean for you?

In this whitepaper, you will learn the impact of the IVDR transition extension and receive tips and strategies to navigate these regulatory changes.
preview_image
Webinar

Drug-Device Combination Products and Article 117

Explore the regulatory complexities of Drug-Device Combination Products. Learn about Article 117 requirements, Notified Body Opinions, and more.
preview_image
Blog

What Makes Usability Testing Crucial for Near-Patient and Self-Testing Devices under IVDR?

It shouldn’t be a surprise that today, “Near-Patient Testing (NPT)” and...
preview_image
Blog

When does Annex XIV apply in Performance Studies, and what key documentation is needed for compliance?

In the European regulatory landscape, conducting performance studies for in...
preview_image
Blog

How to define your Clinical Performance Strategy?

1. Start with a clear intended purpose A strong clinical...
preview_image
Blog

The Holy Grail: Achieving Inspection Readiness

In a previous blog post, we talked about the various activities...